Protagonist Therapeutics: Proprietary peptide technology platform to develop oral targeted therapy-based drugs and injectables for rare diseases. PTG-300 injectable hepcidin mimetic Ph 2 trials ongoing in polycythemia vera and hereditary hemochromatosis; updated Phase 2 results in PV expected by YE 2020. PN-943 oral GI-restricted alpha-4-beta-7 antagonist Ph 2 in ulcerative colitis to begin early 2020; PTG-200, partnered w/ Janssen, oral GI-restricted IL-23R antagonist Ph 2 Crohn’s disease study ongoing.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Platform Technology
521 Cottonwood Drive
Suite 100
Milpitas, CA 95035
United States

Top 10 Holders of Protagonist Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 19.59 5,147,005 113.23 13F 6/30/20
RTW Investments LP 12.87 3,383,208 74.43 13F 6/30/20
Farallon Capital Management LLC 9.51 2,500,000 55.00 13F 6/30/20
Johnson & Johnson Innovation JJDC, Inc. 9.32 2,449,183 53.88 13F 6/30/20
BVF, Inc. 9.01 2,367,288 52.08 13F 6/30/20
Adage Capital Partners GP LLC 8.37 2,200,000 48.40 13F 6/30/20
Adage Capital Management LP 8.37 2,200,000 48.40 Stakes 5/13/20
Baker Bros. Advisors LP 7.27 1,911,446 42.05 13F 6/30/20
Vanguard Group, Inc. (Subfiler) 5.18 1,361,782 29.96 13F 6/30/20
The Vanguard Group, Inc. 4.97 1,309,862 28.82 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.